NCT04149067View on ClinicalTrials.gov

Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

CompletedOBSERVATIONAL
Enrollment

1,080

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin

Evaluation of the effectiveness and safety of the Dapagliflozin treatment.

DRUG

Sitagliptin

Evaluation of the effectiveness and safety of the Sitagliptin treatment.

Trial Locations (1)

41009

Cristóbal Morales Portillo, Seville

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER